APG Asset Management US Inc. Buys 477 Shares of Insulet Co. (NASDAQ:PODD)

APG Asset Management US Inc. raised its stake in shares of Insulet Co. (NASDAQ:PODD) by 2.4% in the second quarter, Holdings Channel reports. The fund owned 20,030 shares of the medical instruments supplier’s stock after acquiring an additional 477 shares during the period. APG Asset Management US Inc.’s holdings in Insulet were worth $3,929,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Research Global Investors increased its position in shares of Insulet by 19.7% during the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after purchasing an additional 1,556,455 shares in the last quarter. Vanguard Group Inc. grew its stake in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after buying an additional 169,506 shares during the last quarter. Baillie Gifford & Co. increased its holdings in shares of Insulet by 30.8% during the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after buying an additional 443,783 shares in the last quarter. William Blair Investment Management LLC raised its stake in shares of Insulet by 3.7% in the first quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock valued at $163,219,000 after acquiring an additional 33,579 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Insulet by 18.7% in the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after acquiring an additional 139,246 shares during the last quarter.

Analysts Set New Price Targets

PODD has been the topic of a number of research analyst reports. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. UBS Group increased their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Barclays increased their price objective on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, BTIG Research dropped their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $231.71.

Insulet Trading Down 1.4 %

Shares of NASDAQ PODD opened at $235.43 on Friday. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $243.98. The firm has a market capitalization of $16.51 billion, a P/E ratio of 71.34, a P/E/G ratio of 4.47 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The company’s 50 day simple moving average is $206.07 and its 200 day simple moving average is $190.01.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. During the same period last year, the company earned $0.38 EPS. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, analysts predict that Insulet Co. will post 3.04 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.